BMO Capital Initiates Coverage On Insmed with Outperform Rating, Announces Price Target of $192
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
BMO Capital analyst Connor Mackay initiates coverage on Insmed (NASDAQ:INSM) with a Outperform rating and announces Price Target of $192.
BMO Capital analyst Connor Mackay initiates coverage on Insmed (NASDAQ:INSM) with a Outperform rating and announces Price Target of $192.